US2018208672A1PendingUtilityA1
Antibodies specific to heterodimers of bcl-2 family and uses thereof
Assignee: EUTROPICS PHARMACEUTICALS INCPriority: May 7, 2008Filed: Aug 15, 2017Published: Jul 26, 2018
Est. expiryMay 7, 2028(~1.8 yrs left)· nominal 20-yr term from priority
Inventors:Michael H. Cardone
G01N 33/5759G01N 33/57492C07K 16/18C07K 2317/622C07K 16/30
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Isolated antibodies specifically binding to heterodimers of the Bcl-2 family and uses thereof for detecting presence of Bcl-2 heterodimers in a patient.
Claims
exact text as granted — not AI-modified1 - 9 . (canceled)
10 . A method for detecting the presence of a heterodimer of the Bcl-2 family in a fixed tissue sample, comprising
(a) contacting an isolated antibody specifically binding to a heterodimer selected from Bim and Mcl-1, Bim and Bcl-2, and Bid and Bcl-2 to a fixed tissue sample suspected of having a heterodimer of the Bcl-2 family; (b) detecting a signal that indicates binding of the antibody to the heterodimer, and (c) determining the presence of the heterodimer in the fixed tissue sample based on the intensity of the signal.
11 - 12 . (canceled)
13 . The method of claim 10 , wherein the fixed tissue sample is a peripheral blood sample, a lymph-node sample, a bone marrow sample, or an organ tissue sample.
14 . The method of claim 10 , wherein the fixed tissue sample is a mitochondrial fraction.
15 - 21 . (canceled)
22 . The method of claim 10 , wherein the fixed tissue sample is a paraffin embedded tissue sample.
23 . The method of claim 10 , wherein the fixed tissue sample is a frozen thin section tissue sample.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.